2021
DOI: 10.1002/14651858.cd014869
|View full text |Cite
|
Sign up to set email alerts
|

Tamoxifen for hepatocellular carcinoma

Abstract: To assess the benefits and harms of tamoxifen in people with hepatocellular carcinoma, irrespective of sex, administered dose, type of formulation, and duration of treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 73 publications
0
0
0
Order By: Relevance